Jianmin Pharmaceutical Group Co Ltd - Asset Resilience Ratio
Jianmin Pharmaceutical Group Co Ltd (600976) has an Asset Resilience Ratio of 20.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 600976 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Jianmin Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Jianmin Pharmaceutical Group Co Ltd asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Jianmin Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Jianmin Pharmaceutical Group Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥966.27 Million | 20.61% |
| Total Liquid Assets | CN¥966.27 Million | 20.61% |
Asset Resilience Insights
- Good Liquidity Position: Jianmin Pharmaceutical Group Co Ltd maintains a healthy 20.61% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Jianmin Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jianmin Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Jianmin Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Jianmin Pharmaceutical Group Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.09% | CN¥1.09 Billion ≈ $159.60 Million |
CN¥4.53 Billion ≈ $662.43 Million |
+1.79pp |
| 2024-12-31 | 22.31% | CN¥954.19 Million ≈ $139.63 Million |
CN¥4.28 Billion ≈ $625.95 Million |
+5.64pp |
| 2023-12-31 | 16.66% | CN¥694.46 Million ≈ $101.62 Million |
CN¥4.17 Billion ≈ $609.90 Million |
-2.00pp |
| 2022-12-31 | 18.66% | CN¥641.38 Million ≈ $93.85 Million |
CN¥3.44 Billion ≈ $503.04 Million |
-0.41pp |
| 2021-12-31 | 19.06% | CN¥538.63 Million ≈ $78.82 Million |
CN¥2.83 Billion ≈ $413.47 Million |
-1.04pp |
| 2020-12-31 | 20.10% | CN¥485.79 Million ≈ $71.09 Million |
CN¥2.42 Billion ≈ $353.71 Million |
+2.87pp |
| 2019-12-31 | 17.22% | CN¥332.17 Million ≈ $48.61 Million |
CN¥1.93 Billion ≈ $282.21 Million |
-4.70pp |
| 2018-12-31 | 21.93% | CN¥377.60 Million ≈ $55.25 Million |
CN¥1.72 Billion ≈ $252.01 Million |
+18.60pp |
| 2017-12-31 | 3.33% | CN¥64.00 Million ≈ $9.36 Million |
CN¥1.92 Billion ≈ $281.56 Million |
-8.57pp |
| 2016-12-31 | 11.89% | CN¥215.00 Million ≈ $31.46 Million |
CN¥1.81 Billion ≈ $264.54 Million |
-10.28pp |
| 2015-12-31 | 22.17% | CN¥355.25 Million ≈ $51.98 Million |
CN¥1.60 Billion ≈ $234.43 Million |
+1.49pp |
| 2014-12-31 | 20.69% | CN¥320.00 Million ≈ $46.83 Million |
CN¥1.55 Billion ≈ $226.35 Million |
+20.68pp |
| 2009-12-31 | 0.01% | CN¥74.94K ≈ $10.97K |
CN¥1.30 Billion ≈ $189.66 Million |
+0.00pp |
| 2008-12-31 | 0.00% | CN¥44.58K ≈ $6.52K |
CN¥1.16 Billion ≈ $169.60 Million |
0.00pp |
| 2006-12-31 | 0.00% | CN¥46.00K ≈ $6.73K |
CN¥1.05 Billion ≈ $153.91 Million |
-0.16pp |
| 2005-12-31 | 0.17% | CN¥1.77 Million ≈ $258.68K |
CN¥1.06 Billion ≈ $155.25 Million |
-0.04pp |
| 2004-12-31 | 0.21% | CN¥1.90 Million ≈ $277.46K |
CN¥924.49 Million ≈ $135.28 Million |
+0.14pp |
| 2003-12-31 | 0.07% | CN¥362.79K ≈ $53.09K |
CN¥532.62 Million ≈ $77.94 Million |
+0.05pp |
| 2002-12-31 | 0.02% | CN¥103.62K ≈ $15.16K |
CN¥453.85 Million ≈ $66.41 Million |
-0.01pp |
| 2001-12-31 | 0.03% | CN¥133.86K ≈ $19.59K |
CN¥398.42 Million ≈ $58.30 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.